Papers/PMID:23352552
Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50,000 individuals.
Lancet (London, England)2013The record
1 finding · 1 compound · 1 endpoint · 1 null
What it reported
How to read these marksEvery finding here is a null result.
What did not
1 finding
folic acid — no detected effect on all-site cancer incidence
Evidence strength: moderate.FindingNull result“Allocation to folic acid treatment did not have any statistically significant effect on overall cancer incidence, with 1904 (7.7%) first events in 24,799 participants allocated folic acid versus 1809 (7.3%) in 24,822 allocated control (RR 1.06; 95% CI 0.99–1.13, p=0.10: Figure 1).”
Quoted verbatim from Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50,000 individuals.. - Study
- meta-analysis
- Dose
- 0.5 to 5 mg folic acid daily in all trials but one (40 mg daily); one trial compared 2.5 mg with 0.02 mg
- Population
- Adults in 13 randomised trials of folic acid versus placebo (10 trials in people with or at high risk of cardiovascular disease, 3 in patients with prior colorectal adenoma); mean age 64 years
Effect 1.06 risk ratio, 95% CI 0.99 to 1.13
Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50,000 individuals.2013PMID:2335255210.1016/S0140-6736(12)62001-7An author is affiliated with a producerPermalink